logo
US posts highest annual measles case tally in 33 years amid Texas outbreak

US posts highest annual measles case tally in 33 years amid Texas outbreak

Yahoo5 hours ago
The annual tally of measles cases in the US is the highest in 33 years, as an ongoing outbreak in west Texas continues to drive cases.
The latest figures mean Americans will have to look back to 1992 to find a worse year with the vaccine preventable disease. The official tally very likely undercounts the scope of the outbreak, experts told the Guardian.
'When you talk to people on the ground, you get the sense that this outbreak has been severely underestimated,' said Dr Paul Offit, director of the vaccine education center at the Children's Hospital of Philadelphia. Confirmed cases appear to be the 'tip of a much bigger iceberg', he said.
Measles was declared eliminated in the US in 2000. However, as the pandemic disrupted routine childhood visits to the doctors and anti-vaccine organizations saw their coffers swell during the pandemic, measles vaccination rates have fallen below a critical threshold to prevent outbreaks in some communities.
As of 4 July, Johns Hopkins University's Center for Outbreak Response Innovation counted 1,277 measles cases. The Centers for Disease Control and Prevention (CDC) reports 1,267 cases, but has not updated its data since 2 July.
'The number of new cases has slowed down, but I don't think there's any reason to suggest this will be our last,' said Dr Peter Hotez, a vaccine expert and dean for the national school of tropical medicine at Baylor College of Medicine in Houston, Texas.
He later added: 'It's a very dark epidemic that never had to happen.'
The latest national tally will eclipse 2019, when unvaccinated members of New York City's isolated orthodox Jewish community drove a large outbreak, and the nation ended the year with 1,274 confirmed measles cases.
Americans will need to look back to 1992 to find a higher annual measles tally. In 1992, the CDC confirmed 2,126 cases, with the largest outbreaks in Kentucky and Texas. Texas has confirmed 753 cases in 2025, according to the state health department, opening up the possibility that Texas could exceed the 1992 annual total as well.
The enormous outbreak comes as Donald Trump's health secretary, Robert F Kennedy Jr, who once ran an influential anti-vaccine group, has injected upheaval into US vaccine policy and spread misinformation about treatments for the disease.
Measles is a viral disease characterized by a top-down rash, high fever, runny nose and red, watery eyes. The virus is one of the most infectious diseases known to medicine. There is no cure for measles. The best way to prevent measles is by getting vaccinated with the measles, mumps and rubella vaccine (MMR), which is 97% effective with two doses.
Although most people recover, as many as one in five infected children require hospitalization; one in 20 get pneumonia and one in 1,000 can develop encephalitis, which can lead to lifelong disability, according to the CDC. The disease can also weaken the host's immune system and lead to more future infections. In rare cases, measles can cause an incurable degenerative brain disorder. The US has already seen three deaths from measles this year, both in otherwise healthy children.
Before a measles vaccine was licensed in 1963, an estimated 3-4 million Americans were sickened each year, 48,000 were hospitalized and an estimated 400-500 died, according to the CDC. From 1994 to 2023 in the US alone, the CDC estimates the measles vaccine saved 85,000 lives and prevented 104m illnesses.
Although the vaccine has been wildly successful, it has also been the target of sustained misinformation by people who have a financial stake in reduced vaccine uptake.
In 1998, a British doctor hypothesized a link between the MMR and increasing autism rates. The doctor, Andrew Wakefield, was later found to have committed fraud, failed to report conflicts of interest and lost his license. The article was retracted.
Reams of science has since examined and re-examined the evidence, and found no link between the MMR vaccine and autism. Still, the debunked connection has found an afterlife as a talking point for anti-vaccine groups who have attracted a vocal minority of parents. The overwhelming majority of Americans still vaccinate children against measles.
Now, alongside longtime anti-vaccine talking points about autism and 'medical freedom', Hotez said a new threat was the, 'very pernicious health and wellness and influencer movement that's got a big profit motive'.
Outbreaks appear to be 'occurring in the same [parts] of the US that had some of the lowest Covid vaccination rates', said Hotez, introducing the possibility that anti-vaccine sentiment is 'spilling over to childhood immunizations'.
In June, Kennedy unilaterally fired all 17 expert members of a CDC advisory panel on vaccines and stacked the committee with seven ideological allies. The advisory committee is a key link in the vaccine distribution pipeline.
Among those allies now serving on the committee are medical professionals with fringe beliefs and known anti-vaccines advocates. In June, the group met for the first time, and said it would form a new committee to re-evaluate the childhood vaccine schedule.
'We've not only eliminated measles, we've eliminated the memory of measles,' said Offit. 'People don't remember how sick this virus can make you – or how dead it can make you.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

Yahoo

time44 minutes ago

  • Yahoo

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S. Celltrion further expands its portfolio, delivering cost-effective and high-quality biologic medicines to wider range of patients in the U.S. JERSEY CITY, N.J., July 7, 2025 /PRNewswire/ -- Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially available in the United States. STOBOCLO is available in 60 mg/mL injection and is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.[1] OSENVELT is available in 120 mg/1.7 mL (70 mg/mL) injection and is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy.[2] "We are pleased to have achieved a global settlement with Amgen regarding our denosumab biosimilars," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "We are proud to introduce our denosumab biosimilars to the U.S. market, offering patients and healthcare professionals a valuable alternative treatment option. Building on our strong heritage in biosimilars, Celltrion remains committed to being a trusted partner for both patients and physicians, while contributing to the overall sustainability of healthcare systems." STOBOCLO and OSENVELT are supported by Celltrion's comprehensive patient support programs designed to help empower patients to navigate their treatment journeys. Celltrion offers a suite of resources, including the Celltrion CONNECT® Patient Support Program and the Celltrion CARES™ Co-pay Assistance Program. Patients who are uninsured may be able to receive STOBOCLO and OSENVELT at no cost. Visit and to learn more. Celltrion's biosimilars portfolio covers the areas of immunology, oncology, gastroenterology, allergy, and endocrinology. About STOBOCLO® (denosumab-bmwo) STOBOCLO® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing PROLIA® (denosumab). STOBOCLO 60 mg/mL injection is approved by the FDA based on comprehensive data and clinical evidence confirming the therapeutic equivalence to PROLIA. In the U.S., STOBOCLO is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. INDICATIONS STOBOCLO® (denosumab-bmwo) is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture to increase bone mass in men with osteoporosis at high risk for fracture or in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer of glucocorticoid-induced osteoporosis in men and women at high risk for fracture to increase bone mass in women at high risk for fracture receiving an adjuvant aromatase inhibitor therapy for breast cancer IMPORTANT SAFETY INFORMATION WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease, including those on dialysis, face a higher risk of severe hypocalcemia after denosumab administration, with reported cases leading to hospitalization, life-threatening events, and fatalities. The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients Before starting STOBOCLO® (denosumab-bmwo) in advanced chronic kidney disease patients, assess for CKD-MBD. Treatment should be supervised by a healthcare provider experienced in diagnosing and managing CKD-MBD. STOBOCLO is contraindicated in hypocalcemia, pregnant women, and in patients with known hypersensitivity to denosumab. Severe Hypocalcemia: Ensure adequate calcium and vitamin D; monitor for severe hypocalcemia. Drug Products with Same Active Ingredient: Do not use with other denosumab products. Hypersensitivity: If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of STOBOCLO. Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on STOBOCLO. Conduct oral exams before treatment; maintain oral hygiene; consider discontinuation of STOBOCLO if ONJ develops. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of STOBOCLO therapy should be considered, pending a benefit-risk assessment, on an individual basis. Multiple Vertebral Fractures (MVF) Following Discontinuation of Treatment: Increased risk post-discontinuation of denosumab; transition to alternative therapy if discontinuing STOBOCLO. Serious Infections: Higher risk in denosumab users; assess benefit-risk profile, especially in immunocompromised patients. Assess the benefit-risk profile before starting STOBOCLO and reconsider its use if serious infections develop. Dermatologic Adverse Reactions: Consider discontinuing STOBOCLO if severe dermatitis, eczema, or rashes occur. Musculoskeletal Pain: Consider discontinuation of STOBOCLO if severe pain develops. Bone Turnover Suppression: In clinical trials in women with postmenopausal osteoporosis, denosumab significantly suppressed bone remodelling; patients should be monitored for these outcomes. Hypercalcemia in Pediatrics Patients with Osteogenesis Imperfecta: Not for pediatric use; hypercalcemia reported in patients osteogenesis imperfecta treated with denosumab products. Most common Adverse Reactions: In (>5%) of patients with: Postmenopausal osteoporosis were back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis has been reported in clinical trials. Male osteoporosis were back pain, arthralgia, and nasopharyngitis. Glucocorticoid-induced osteoporosis (> 3%) were back pain, hypertension, bronchitis, and headache. Bone loss due to hormone ablation for cancer (≥ 10%) were arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials. For more information, see Full Prescribing Information. About OSENVELT® (denosumab-bmwo) OSENVELT® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing XGEVA® (denosumab). OSENVELT 120 mg/1.7 mL (70 mg/mL) injection is approved by the FDA based on a robust clinical trial and comprehensive data confirming the therapeutic equivalence to XGEVA. In the U.S., OSENVELT is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy. INDICATION OSENVELT® (denosumab-bmwo) is indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. IMPORTANT SAFETY INFORMATION Contraindications: Patients with hypocalcemia or with known clinically significant hypersensitivity to denosumab products. Drug Products with Same Active Ingredient. Patients receiving OSENVELT should not receive other denosumab products concomitantly. Hypersensitivity. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of OSENVELT. Hypocalcemia. Severe hypocalcemia can occur, and fatal cases have been reported. Monitor calcium levels and calcium and vitamin D intake. Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on OSENVELT. Conduct oral exams and appropriate preventive dentistry before and during treatment; maintain oral hygiene and avoid invasive dental procedures; consider discontinuation of OSENVELT if ONJ develops. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of OSENVELT therapy should be considered, pending a benefit-risk assessment, on an individual basis. Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons. Clinically significant hypercalcemia, potentially requiring hospitalization, can occur within a year after stopping denosumab in patients with giant cell tumor of bone or growing skeletons; monitor serum calcium and manage calcium and vitamin D needs post-discontinuation. Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation. Increased risk post-discontinuation of denosumab; evaluate for risk for vertebral fractures after discontinuing OSENVELT. Embryo-Fetal Toxicity. Denosumab may cause fetal harm; verify pregnancy status before starting OSENVELT and advise effective contraception during treatment and for 5 months after the last dose. Most common Adverse Reactions: Bone Metastasis from Solid Tumors (≥ 25%) were fatigue/asthenia, hypophosphatemia, and nausea. In patients (≥ 10%) with: Multiple Myeloma were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache; Giant Cell Tumor of Bone were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity. Hypercalcemia of Malignancy (> 20%) were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea. For more information, see Full Prescribing Information. About Celltrion, Inc. Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook. About Celltrion USA Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit and stay updated with our latest news and events on our social media - LinkedIn. FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. Trademarks STOBOCLO® and OSENVELT® are registered trademarks of Celltrion, and XGEVA® are registered trademarks of Amgen Inc. References [1] STOBOCLO U.S. prescribing information (2025) [2] OSENVELT U.S. prescribing information (2025) US-CT-P41-25-00006 For further information please contact:Andria Arenaaarena@ 516-578-0057 View original content to download multimedia: SOURCE Celltrion Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Governor reveals ‘Make Oklahoma Healthy Again' plan with RFK for bans on soda, red dye
Governor reveals ‘Make Oklahoma Healthy Again' plan with RFK for bans on soda, red dye

Yahoo

timean hour ago

  • Yahoo

Governor reveals ‘Make Oklahoma Healthy Again' plan with RFK for bans on soda, red dye

Gov. Kevin Stitt, center, pens his name during a ceremonial signing of an executive order to "Make Oklahoma Healthy Again," as Robert F. Kennedy Jr., right, the nation's secretary of health, and other supporters look on Thursday, June 26, 2025. (Photo by Janelle Stecklein/Oklahoma Voice) OKLAHOMA CITY — In a move quickly panned by licensed health care providers, Gov. Kevin Stitt announced Thursday that he planned to 'Make Oklahoma Healthy Again' by urging state agencies to stop supporting public water fluoridation, removing red food dyes from school and prison meals, and by asking the federal government to approve a request that bans food stamp recipients from purchasing soda and candy. Stitt's pledge came minutes after Robert F. Kennedy Jr., the nation's secretary of Health and Human Services, criticized the state for having the 47th worst health outcomes during a raucous 'MOHA' kickoff rally that drew hundreds of people to the state Capitol. Oklahoma has become the latest conservative state to submit a waiver to the U.S. Department of Agriculture that seeks to ban the state's Supplemental Nutrition Assistance Program recipients from using their benefits to buy sodas, candies and other confectionery items, Stitt said. Tax dollars will no longer 'continue to fund foods that are making people sick,' he said. State officials will also work with the U.S. Department of Agriculture to find more ways to promote healthly eating and to make food stamp funding go further. 'Eating healthy foods today is going to reduce health care spending and dietary related illnesses later on in life,' Stitt said. The Republican governor also said he's instructed the Oklahoma State Department of Health to stop recommending fluoride in public water. 'Cities and water districts, they can still choose to do what they want, based on their constituents and the science, but it's no longer going to be a recommendation for the state health department,' Stitt said. And Stitt said he's instructed all state agencies that provide meals to Oklahomans to discontinue their use of artificial dyes. He also plans to convene an advisory counsel to recommend other changes that can improve health outcomes across the state. Stitt's plans immediately faced criticism from licensed medical providers who showed up en masse at the rally, holding signs reading 'Support Evidence-Based Health Care', 'Encourage Immunizations' and 'Protect Medicaid.' Dr. Steven Crawford, chair of the Oklahoma Alliance for Healthy Families, said it would be 'disastrous' for children's health to remove fluoride from water. 'We do know that appropriate public water fluoridation prevents cavities,' he said. 'And how do you help children get better nutrition when they don't have adequate dentition or teeth to be able to eat the food? So I am so sad that the governor is advocating removing appropriate fluoride from public water.' Crawford, who practices medicine in Oklahoma City, said fluoridation of public water and immunizations are two of the major health benefits over the past century and have been critical to improving the state's and nation's health outcomes. He said removing candy and sugary drinks from the list of approved food stamp items isn't inappropriate, but Stitt neglected to mention that many recipients already don't get enough resources to be able to buy healthy foods. The governor also didn't discuss increasing food stamp funding to ensure children are getting adequate nutrition, particularly during the summer months when they are not eating at school, he said. Kennedy, who participated in a staged, ceremonial executive order signing with Stitt, praised the governor's actions. 'I am so gratified by these actions that are being taken by Gov. Stitt to make Oklahoma healthy again,' Kennedy said. Spectators heckled Kennedy throughout his speech that focused on America's soaring rates of obesity, diabetes and autism, declines in the nation's fertility rates and a drop in American teenage boys' testosterone levels. Kennedy, who has been criticized as being a vaccine skeptic, did not mention immunizations during his address. At one point, a state trooper could be seen escorting two bystanders from the crowd after one began shouting something unintelligible at Kennedy. A spokesperson for the Oklahoma Highway Patrol did not immediately respond to a request for comment about the encounter. Kennedy said when people ask him if he's taking soda and sugary drinks away from the Americans, he tells them that they should have the right to drink a bottle of soda. 'We live in a country where we have individual freedom,' he said. The federal government just should not be paying for it, he said. 'We're paying for them at the front end by buying soda for the poorest Americans, and then we're paying for it (on) the back end with this diabetes, for Medicaid and Medicare,' Kennedy said. 'And it doesn't make any sense. We are poisoning the American people.' He said electing leaders like Stitt will change the way we do things in the U.S. to give American children a better chance of growing up healthy. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX SUPPORT: YOU MAKE OUR WORK POSSIBLE

Children in the U.S. Are Dying at a Higher Rate than Kids in Similar Countries, Study Says
Children in the U.S. Are Dying at a Higher Rate than Kids in Similar Countries, Study Says

Yahoo

timean hour ago

  • Yahoo

Children in the U.S. Are Dying at a Higher Rate than Kids in Similar Countries, Study Says

A new study published by the Journal of the American Medical Association suggested that American children are in worse health than their counterparts in other countries Babies are 1.78 times more likely to perish, and children aged 1 to 19 are 1.8 times more likely to die than those in comparable countries Author Dr. Chris Forrest pointed out that the worrying trends are like a "proverbial canary in the coal mine," pointing to a larger problem within AmericaA new study shed light on a worrying trend in the health of American children. In a Monday, July 7 study published by the Journal of the American Medical Association (JAMA), research suggested that American children are in worse health than those growing up in other developed countries. Additionally, they are progressively less healthy than they were in previous years. The study examined trends in the health of children between 2007 and 2023. It found that in the U.S., "children's health has deteriorated across a broad spectrum of indicators." Data and trends between 2007 and 2022 suggest that infants are 1.78 times more likely to die in the U.S. than in other countries of a similar standing. Children between the ages of 1 and 19 were also 1.8 times more likely to die than their counterparts in other countries. In the latter group, there was a marked difference in the likelihood of dying from "firearm-related incidents" and "motor vehicle crashes," with American children dramatically more likely to perish as a result of these avoidable tragedies. In perspective, this amounts to approximately 54 more children dying per day in America, per the study. The findings come after deaths in the U.S. were in line with other countries in the 1960s. The study also suggested that American children were 14% more likely to suffer a chronic condition than their counterparts. The likelihood of being diagnosed with a chronic condition also increased from 39.9% to 45.7% in America between 2011 and 2023. Examples of chronic issues that children are now battling include the likes of "depression, anxiety and loneliness increased, as did rates of autism, behavioral conduct problems, developmental delays, speech language disorders and attention-deficit hyperactivity disorders." 'I think we all should be disturbed by this,' Dr. Chris Forrest, a professor of pediatrics at Children's Hospital of Philadelphia and director of the Applied Clinical Research Center, told CNN. 'Kids in this country are really suffering.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. Speaking to the outlet, Forrest noted that he has seen a change in his patients since he started practicing medicine in the '90s. He attributed that to a variety of elements, saying that it comes together to create "a very toxic environment." While the Make America Healthy Again Commission, fronted by U.S. Secretary of Health and Human Services Robert F. Kennedy has targeted chemicals in food and elsewhere as a cause for America's worsening health, Forrest said that the problem runs much deeper. "It's not just the chemicals. It's not just the food and the iPhones. It's a much broader. It's much deeper. It's what we call the developmental ecosystem, and it makes it very challenging to change it,' Forrest told CNN. 'That's a hard answer for people who want a pithy message that tells them how to fix the issues. It's about where they're growing up, where they're going to school, they're playing, where their families live, their neighborhoods, and it's not just one population. It's the whole nation that needs help.' Another element that he highlighted was that "women are also suffering in this country," suggesting that children are being born into already sickening households. Citing the research, he said, 'This means the same kid born in this country is much more likely to die than if they were born in Germany or Denmark. Why are we allowing this to happen?' For Forrest, the research is comparable to "the proverbial canary in the coal mine." "When [children's] health is deteriorating, that means the foundation of our nation is also deteriorating," he concluded. Read the original article on People

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store